![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1405378
³»½Ã°æÇÏ Ç÷°üäÃë : ½ÃÀå Á¡À¯À² ºÐ¼®, »ê¾÷ µ¿Çâ ¹× Åë°è, ¼ºÀå ¿¹Ãø(2024-2029³â)Endoscopic Vessel Harvesting - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2024 - 2029 |
³»½Ã°æÇÏ Ç÷°üäÃë ½ÃÀåÀº 2024³â¿¡ 5¾ï ´Þ·¯·Î ÃßÁ¤µÇ°í, 2029³â¿¡´Â 5¾ï 8,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ¿¹Ãø ±â°£ÀÇ CAGRÀº 3.16%¸¦ ±â·ÏÇÒ Àü¸ÁÀÔ´Ï´Ù.
COVID-19 ÆÒµ¥¹Í ¶§¹®¿¡ ÆÒµ¥¹Í Ãʱ⿡´Â ½ÉÀåÄ¡·á¸¦ À§ÇØ º´¿øÀ̳ª Áø·á¼Ò¸¦ ¹æ¹®ÇÏ´Â »ç¶÷ÀÌ °¨¼ÒÇÏ°í ³»½Ã°æÇÏ Ç÷°üäÃë µî ¼ö¿ä°¡ °¨¼èÇß½À´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 8¿ù¿¡ Journal of American College of Cardiology°¡ ¹ßÇ¥ÇÑ ³í¹®¿¡ µû¸£¸é, ½ÉÇ÷°ü°è ÁúȯÀÇ ÀÇ·á ½Ã¼³ ÀÔ¿ø¿¡ °üÇÑ ÀϺΠ¿¬±¸¿¡¼´Â ÆÒµ¥¹Í Áß¿¡ ½ÉÇ÷°ü°è Áúȯ °ü·Ã ÀÔ¿øÀÌ Å©°Ô °¨¼ÒÇß½À´Ï´Ù. ¶ÇÇÑ Àα¸ ¼öÁØÀÇ ½ÉÇ÷°ü Áúȯ »ç¸Á·ü¿¡ °üÇÑ ¿¬±¸´Â ±¹°¡¸¶´Ù ´Ù¸£¸ç ´ëºÎºÐÀÌ °¨¼Ò¸¦ º¸¿´´Ù°í ³í¹®¿¡¼ ¾ð±ÞÇß½À´Ï´Ù. ÀÌ¿Í °°ÀÌ COVID-19 ÆÒµ¥¹ÍÀº ³»½Ã°æÇÏ Ç÷°üäÃ븦 Æ÷ÇÔÇÑ Àüü ½ÉÇ÷°ü Áúȯ ½ÃÀåÀÌ ÃÖÃÊÀÇ ÆÒµ¥¹Í ½Ã¿¡ Å« ¿µÇâÀ» ¹Þ¾Ò½À´Ï´Ù. ±×·¯³ª ÆÒµ¥¹ÍÀÌ ÁøÁ¤µÇ°í ½ÉÀåÀÇ·á°¡ Á¤»óÀ¸·Î µ¹¾Æ¿Ô±â ¶§¹®¿¡ Á¶»ç ´ë»ó ½ÃÀåÀº Á¶»ç ¿¹Ãø ±â°£ µ¿¾È ¾ÈÁ¤µÈ ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù.
Á¶»ç ´ë»ó ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀ¸·Î´Â °ü»ó µ¿¸Æ ÁúȯÀ̳ª ¸»ÃÊ µ¿¸Æ Áúȯ µîÀÇ ½ÉÇ÷°ü°è ÁúȯÀÇ À¯º´·ü Áõ°¡, Á¾·¡ÀÇ ¹æ¹ý¿¡ ´ëÇÑ ÀÌÁ¡¿¡ ÀÇÇÑ Àúħ½À äÃë¿¡ ´ëÇÑ ±âÈ£ÀÇ ³ô¾ÆÁü, ³ëÀÎ Àα¸ Áõ°¡ µîÀ» µé ¼ö ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2021³â 9¿ù CDC º¸°í¼¿¡ µû¸£¸é ¸»ÃÊ µ¿¸Æ Áúȯ(PAD)Àº ³²³à ¸ðµÎ ¾Î°í ÀÖÁö¸¸ ¾ÆÇÁ¸®Ä«°è ¹Ì±¹ÀÎÀº ¹ßº´ À§ÇèÀÌ ³ô´Ù°í ÇÕ´Ï´Ù. ºñÈ÷½ºÆÐ´Ð°è ¹éÀΰú ºñ±³ÇÒ ¶§, È÷½ºÆÐ´Ð°è´Â PADÀÇ ¹ßº´·üÀÌ °°Àº Á¤µµ·Î ¾à°£ ³ôÀ» ¼ö ÀÖ½À´Ï´Ù. PAD´Â ¹Ì±¹ÀÇ 40¼¼ ÀÌ»ó ¾à 650¸¸ ¸íÀ¸·Î ¹ßº´Çϰí ÀÖ½À´Ï´Ù. µû¶ó¼ PADÀÇ À¯º´·ü Áõ°¡´Â ¸»ÃÊ ½ºÅÙÆ®¿¡ ´ëÇÑ ¼ö¿ä¸¦ Áõ°¡½ÃÄÑ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
°Ô´Ù°¡ °ü»óµ¿¸Æ Áúȯ°ú ¸»Ãʵ¿¸Æ ÁúȯÀ» ÀÏÀ¸Å°±â ½¬¿î ³ëÀÎ Àα¸´Â ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î À¯¿£ World Population Prospects 2022ÀÇ µ¥ÀÌÅÍ¿¡ µû¸£¸é 65¼¼ ÀÌ»óÀÇ ¼¼°è Àα¸¿¡¼ Â÷ÁöÇÏ´Â ºñÀ²Àº 2022³âÀÇ 10%¿¡¼ 2050³â¿¡´Â 16%·Î »ó½ÂÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¶ÇÇÑ 2050³â±îÁö Àü ¼¼°è 65¼¼ ÀÌ»ó Àα¸´Â 5¼¼ ¹Ì¸¸ ¾î¸°ÀÌ ¼öÀÇ 2¹è ÀÌ»ó, 12¼¼ ¹Ì¸¸ ¾î¸°ÀÌ ¼ö¿Í °ÅÀÇ µ¿ÀÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
°Ô´Ù°¡ 2021³â 3¿ù Journal of Thoracic Disease ÀâÁö°¡ ¹ßÇ¥ÇÑ ³í¹®¿¡ µû¸£¸é Àúħ½ÀÁ¤¸Æ ¹× Ç÷°üäÃ븦 ¹ÞÀº ȯÀÚ´Â °³º¹Ã¤Ãë¼úÀ» ¹ÞÀº ȯÀÚº¸´Ù 4ÀÏ »¡¸® ±Í°¡Çß´Ù´Â ¿¬±¸°á°ú°¡ ÀÖ½À´Ï´Ù. ÀÌ ¶§¹®¿¡ Àúħ½À äÇ÷ÀÇ ÀåÁ¡ Áõ°¡µµ ½ÃÀå ¼ºÀåÀ» µÞ¹ÞħÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
µû¶ó¼ °ü»óµ¿¸Æ ÁúȯÀ̳ª ¸»Ãʵ¿¸Æ Áúȯ°ú °°Àº ÁúȯÀÇ À¯º´·ü »ó½Â, ³ëÀÎ Àα¸ Áõ°¡, ħ½ÀÀû äÃë ÀýÂ÷ÀÇ ÀåÁ¡ Áõ°¡ µî À§ÀÇ ¿äÀÎÀ¸·Î ÀÎÇØ Á¶»çµÈ ½ÃÀåÀº Á¶»çÀÇ ¿¹Ãø ±â°£ µ¿¾È ¼ºÀåÀ» °æÇèÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±×·¯³ª ´ëü Ä¡·á¹ýÀÇ °¡¿ë¼º°ú ºÒÃæºÐÇÑ »óȯ ½Ã³ª¸®¿À¿Í °°Àº ¿äÀÎÀº ½ÃÀå ¼ºÀåÀ» ¹æÇØÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
°ü»óµ¿¸Æ Áúȯ(CAD)Àº °ü»óµ¿¸ÆÀÇ ÇùÂø°ú Æó»öÀ¸·Î, ÀϹÝÀûÀ¸·Î ÇöóÅ©ÀÇ ÃàÀû ¶§¹®ÀÔ´Ï´Ù. ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀº °ü»óµ¿¸Æ Áúȯ(CAD)ÀÇ À¯º´·ü Áõ°¡¿Í ³ë³â Àα¸ Áõ°¡ÀÔ´Ï´Ù.
2022³â 7¿ù PubMed CentralÀÌ ¹ßÇ¥ÇÑ ³í¹®¿¡ µû¸£¸é, °ü»óµ¿¸Æ ÁúȯÀº °ü»óµ¿¸Æ¼º ½ÉÀå ÁúȯÀ¸·Îµµ ¾Ë·ÁÁ® ÀÖÀ¸¸ç, Çù½ÉÁõ, ½É±Ù°æ»ö(MI), ½ÉºÎÀü µîÀÇ ÁúȯÀ» ÀÏÀ¸Å°´Â ½É±Ù °ü·ùÀÇ ÀúÇÏ¿¡ ±âÀÎÇÏ´Â °æ¿ì°¡ ¸¹À¸¸ç, ½ÉÇ÷°ü Áúȯ ÀüüÀÇ 3ºÐÀÇ1-2ºÐÀÇ1À» Â÷ÁöÇÕ´Ï´Ù. µû¶ó¼ °ü»óµ¿¸Æ ÁúȯÀº ºÎ´ãÀÌ Å©¹Ç·Î Á¶»ç ´ë»ó ºÎ¹®Àº ÀÌ ¿¬±¸ÀÇ ¿¹Ãø ±â°£ µ¿¾È ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
°Ô´Ù°¡ 2022³â 6¿ù¿¡ Healthdirect Australia°¡ °ËÅäÇÑ ³í¹®¿¡ µû¸£¸é °ü»óµ¿¸Æ ½ÉÀå ÁúȯÀº È£ÁÖ¿¡¼ °¡Àå ÈçÇÑ »çÀÎÀ̸ç, ±× À§Çè ÀÎÀÚ´Â Èí¿¬, °úµµÇÑ À½ÁÖ, ¿îµ¿ ºÎÁ·, »çȸÀû °í¸³, °ú´Ù üÁßÀ̳ª ºñ¸¸ µîÀÌ ÀÖ½À´Ï´Ù. ÀÌ¿Í °°ÀÌ ¿©·¯ ³ª¶ó¿¡¼ CADÀÇ ºÎ´ãÀÌ Å©¹Ç·Î Ä¡·á¸¦ À§ÇÑ ³»½Ã°æÇÏ Ç÷°üäÃëÀÇ Ã¤¿ëÀÌ ÃËÁøµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¶ÇÇÑ ³ëÈ¿Í °ü·ÃµÈ CAD À§Çè Áõ°¡ ¹× ¼¼°è ³ëÀÎ Àα¸ Áõ°¡µµ ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎÀÔ´Ï´Ù. ¿¹¸¦ µé¾î, NCBI°¡ 2022³â 11¿ù¿¡ °»½ÅÇÑ ³í¹®¿¡ µû¸£¸é, CAD ¹ß»ý·üÀº ¼ºº°¿¡ °ü°è¾øÀÌ ¿¬·É¿¡ µû¶ó »ó½ÂÇÕ´Ï´Ù. °Ô´Ù°¡, CAD ¿¬±¸¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡´Â ÷´Ü ³»½Ã°æÇÏ Ç÷°üäÃ븦 ½ÃÀå¿¡ °¡Á®¿Ã °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ÀÌ¿Í °°ÀÌ CAD ºÎ´ã Áõ°¡, ³ë³â Àα¸ Áõ°¡, CAD ¿¬±¸ ÅõÀÚ Áõ°¡ µî À§ÀÇ ¿äÀÎÀº ºÎ¹®ÀÇ ¼ºÀåÀ» µÞ¹ÞħÇÒ °ÍÀ¸·Î ±â´ëµÇ°í ÀÖ½À´Ï´Ù.
ºÏ¹Ì´Â °ü»óµ¿¸Æ Áúȯ°ú ¸»Ãʵ¿¸Æ Áúȯ°ú °°Àº Áúº´ ºÎ´ã Áõ°¡, ³ë³â Àα¸ Áõ°¡, ÁÖ¿ä ½ÃÀå ±â¾÷ÀÇ Á¦Ç° Ãâ½Ã·Î ³»½Ã°æÇÏ Ç÷°üäÃë ½ÃÀå¿¡¼ Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ij³ª´Ù Åë°è±¹(Statistics Canada)ÀÌ 2022³â 7¿ù ¹ßÇ¥ÇÑ µ¥ÀÌÅÍ¿¡ µû¸£¸é ij³ª´ÙÀÇ 65¼¼ ÀÌ»ó Àα¸´Â ¾à 733¸¸ 605¸íÀ¸·Î Ãß»êµÇ¾úÀ¸¸ç ÃÑ Àα¸ÀÇ 18.8%¸¦ Â÷ÁöÇÏ¿´½À´Ï´Ù. µû¶ó¼ ³ë³â Àα¸´Â ¸»ÃÊ µ¿¸Æ Áúȯ¿¡ °É¸®±â ½±±â ¶§¹®¿¡ ³ë³â Àα¸ Áõ°¡´Â ³»½Ã°æÇÏ Ç÷°üäÃë ¼ö¿ä¸¦ Áõ°¡½ÃÄÑ Áö¿ª ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
2021³â 6¿ù¿¡ Circulation Research¿¡ °ÔÀçµÈ ³í¹®¿¡ µû¸£¸é ¸»Ãʵ¿¸Æ ÁúȯÀº ¹Ì±¹¿¡¼ 850¸¸¸íÀÇ ¼ºÀÎÀÌ ÀÌȯÇϰí ÀÖ´Â °ÍÀ¸·Î ÃßÁ¤µÇ¾ú°í À¯º´·üÀº 7%¿´½À´Ï´Ù. ±×·¯¹Ç·Î ÀÌ ³ª¶ó¿¡¼ PAD ÁúȯÀÇ À¯º´·ü Áõ°¡´Â ´Ù¾çÇÑ Ä¡·á ÀýÂ÷ ¼ö¿ä¸¦ µÞ¹ÞħÇϰí Àֱ⠶§¹®¿¡ ¿¹Ãø ±â°£ µ¿¾È ³»½Ã°æÇÏ Ç÷°üäÃë ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
µû¶ó¼ CAD ¹× PAD ºÎ´ã Áõ°¡, ³ë³â Àα¸ Áõ°¡ µî À§ÀÇ ¿äÀÎÀº ºÎ¹® ¼ºÀåÀ» µÞ¹ÞħÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
³»½Ã°æÇÏ Ç÷°üäÃë ½ÃÀåÀº ÅëÇÕµÈ Æ¯¼ºÀ» °¡Áö°í ÀÖ½À´Ï´Ù. ½ÃÀå ¼ºÀå¿¡ Å©°Ô ±â¿©ÇÏ´Â ±â¾÷Àº ¸Å¿ì Àû½À´Ï´Ù. Á¦Ç° Çõ½Å°ú ÷´Ü ±â¼ú °³¹ßÀ» À§ÇÑ Áö¼ÓÀûÀÎ ¿¬±¸°³¹ß Ȱµ¿Àº ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷Àº Ä¡¿ÇÑ °æÀïÀ» À¯ÁöÇϱâ À§ÇØ ´Ù¾çÇÑ Àü·«Àû ¼ö´ÜÀ» äÅÃÇϰí ÀÖ½À´Ï´Ù. ±× Áß¿¡´Â Getinge AB, Terumo Corporation, LivaNova PLC, Medical Instruments Spa, KARL STORZ SE & Co.KG µîÀÌ ÀÖ½À´Ï´Ù.
The endoscopic vessel harvesting market is valued at USD 0.5 billion in 2024 and is expected to reach USD 0.58 billion by 2029, registering a CAGR of 3.16% over the forecast period.
Due to the COVID-19 pandemic, the number of visits to hospitals and clinics for cardiac care decreased during the early pandemic, dampening the demand for procedures such as endoscopic vessel harvesting. For instance, according to an article published by the Journal of American College of Cardiology in August 2022, a few studies of health facility admissions for cardiovascular diseases found significant decreases in cardiovascular disease-related hospital admissions during the pandemic. Also, the article stated that studies of population-level cardiovascular disease mortality differed across countries, with most showing decreases. Thus, due to the COVID-19 pandemic, the overall cardiovascular disease market, including endoscopic vessel harvesting, was significantly impacted during the initial pandemic. However, as the pandemic has subsided, cardiac care has returned to normal, so the studied market is expected to have stable growth during the forecast period of the study.
Factors driving the growth of the studied market include the increasing prevalence of cardiovascular diseases such as coronary artery disease and peripheral artery disease, growing preference for minimally invasive harvesting owing to its advantages over conventional methods, and the rising geriatric population. For instance, according to the CDC Report in September 2021, peripheral artery disease (PAD) affects both men and women, but African Americans are at a higher risk of developing it. Compared to non-Hispanic white people, Hispanics may have similar to slightly higher rates of PAD. PAD affects approximately 6.5 million people in the United States aged 40 and up. Thus, the rising prevalence of PAD is expected to increase the demand for peripheral stents, thereby boosting market growth.
Additionally, the senior population, more prone to developing coronary artery disease and peripheral artery diseases, is anticipated to drive market growth. For instance, as per UN World Population Prospects 2022 data, the share of the global population aged 65 years or above is projected to rise from 10% in 2022 to 16% in 2050. Also, it is estimated that by 2050, the number of persons aged 65 years or over worldwide is projected to be more than twice the number of children under age 5 and about the same as the number of children under age 12.
Furthermore, according to an article published by the Journal of Thoracic Disease in March 2021, a study showed that patients with minimally invasive vein or vessel harvesting went home four days earlier than patients with open harvesting procedures. This suggests that the increasing advantages of minimally invasive harvesting procedures are also expected to boost the market's growth.
Hence, due to the factors above, such as the rising prevalence of diseases such as coronary artery disease and peripheral artery disease, the rising geriatric population, and the increasing advantages of minimally invasive harvesting procedures, the studied market is expected to experience growth during the forecast period of the study. However, factors such as the availability of alternative treatment methods and poor reimbursement scenarios are expected to impede the market's growth.
Coronary artery disease (CAD) is a narrowing or blockage of the coronary arteries, usually due to plaque buildup. The growth of the segment is the rising prevalence of coronary artery disease (CAD) and the rising geriatric population.
According to an article published by PubMed Central in July 2022, coronary artery disease, also known as coronary heart disease, is often caused by decreased myocardial perfusion that causes diseases such as angina, myocardial infarction (MI), and heart failure, among others, and accounts for one-third to one-half of all cardiovascular diseases. Thus, due to the high burden of coronary artery disease, the studied segment is expected to experience growth during the forecast period of the study.
Furthermore, according to an article reviewed by Healthdirect Australia in June 2022, coronary heart disease is the most common cause of death in Australia, and several risk factors for this include smoking, excessive alcohol consumption, lack of exercise, social isolation, and being overweight or obese. Thus, the high burden of CAD in various countries is expected to boost the adoption of endoscopic vessel harvesting procedures for its treatment.
Moreover, the increased risk of CAD with increasing age and the rising geriatric population worldwide is another major factor driving the segment growth. For instance, according to an article updated by NCBI in November 2022, the incidence of CAD rises with age, regardless of gender. Additionally, the increasing investment in CAD research is expected to bring up advanced endoscopic vessel harvesting procedures in the market.
Thus, the factors above, such as the rising burden of CAD, the increasing geriatric population, and the increasing investment in research for CAD, are expected to boost the segment growth.
North America is expected to hold a significant market share in the endoscopic vessel harvesting market due to the rising burden of diseases such as coronary artery disease and peripheral arterial disease coupled with the rising geriatric population and the product launches by key market players.
According to the data published by Statistics Canada in July 2022, it was estimated that around 7,330,605 people were aged 65 years or older in Canada, and this accounted for 18.8% of the total population. Thus, as the geriatric population is more prone to peripheral arterial diseases, the rising geriatric population is expected to increase the demand for endoscopic vessel harvesting procedures, thereby driving market growth in the region.
According to an article published in Circulation Research in June 2021, peripheral arterial disease was estimated to affect 8.5 million adults in the United States, with a prevalence of 7%. Thus, the growing prevalence of PAD diseases in the country has boosted the demand for various treatment procedures; thereby, it is anticipated to drive the growth of the endoscopic vessel harvesting market over the forecast period.
Thus, the factors above, such as the rising burden of CAD and PAD and the increasing geriatric population, are expected to boost the segment growth.
The endoscopic vessel harvesting market is consolidated in nature. There has been a presence of very few companies that are significantly contributing to the market growth. Product innovation and ongoing R&D activities to develop advanced technologies have helped boost the market's growth. The key players in the market are adopting various strategic moves to sustain the intense competition. Some players are Getinge AB, Terumo Corporation, LivaNova PLC, Medical Instruments Spa, and KARL STORZ SE & Co. KG among others.